Although heterozygous loss of BCMA is frequent in multiple myeloma before CAR T cell infusion, BCMA loss as a resistance-driving mechanism is nevertheless less common than CD19- relapse after CD19 CAR.137. Here, TNFRSF17 is linked to plasma cell myeloma.